Nothing for something: Marketing cancer drugs to physicians increases prescribing without improving mortality

被引:0
作者
Carey, Colleen [1 ,2 ]
Daly, Michael [1 ]
Li, Jing [3 ]
机构
[1] Cornell Univ, Cornell, NY 14850 USA
[2] Natl Bur Econ Res, Cambridge, MA USA
[3] UNIV WASHINGTON, Washington, DC USA
关键词
Analysis of health care markets; Information and product quality; Search; Learning; SELF-SELECTION; IMPACT;
D O I
10.1016/j.jpubeco.2025.105311
中图分类号
F [经济];
学科分类号
02 ;
摘要
Physicians commonly receive marketing-related transfers from drug firms. We examine the impact of these relationships on the prescribing of physician-administered cancer drugs in Medicare. We find that prescribing of the associated drug increases 4% in the twelve months after a payment is received, with the increase beginning sharply in the month of payment and fading out within a year. A marketing payment also leads physicians to begin treating cancer patients with lower predicted mortality. While payments result in greater expenditure on cancer drugs, there are no associated improvements inpatient mortality.
引用
收藏
页数:10
相关论文
共 54 条
  • [1] Europe's Tired, Poor, Huddled Masses: Self-Selection and Economic Outcomes in the Age of Mass Migration
    Abramitzky, Ran
    Boustan, Leah Platt
    Eriksson, Katherine
    [J]. AMERICAN ECONOMIC REVIEW, 2012, 102 (05) : 1832 - 1856
  • [2] Abt Associates, 2021, Technical Report
  • [3] Bundled Payment vs. Fee-for-Service: Impact of Payment Scheme on Performance
    Adida, Elodie
    Mamani, Hamed
    Nassiri, Shima
    [J]. MANAGEMENT SCIENCE, 2017, 63 (05) : 1606 - 1624
  • [4] Drug Diffusion through Peer Networks: The Influence of Industry Payments
    Agha, Leila
    Zeltzer, Dan
    [J]. AMERICAN ECONOMIC JOURNAL-ECONOMIC POLICY, 2022, 14 (02) : 1 - 33
  • [5] Origins of the Opioid Crisis and its Enduring Impacts*
    Alpert, Abby
    Evans, William N.
    Lieber, Ethan M. J.
    Powell, David
    [J]. QUARTERLY JOURNAL OF ECONOMICS, 2022, 137 (02) : 1139 - 1179
  • [6] Angell Marcia., 2005, The Truth about the Drug Companies: How They Deceive Us and What to Do about It
  • [7] [Anonymous], 2019, Global Burden of Disease Study 2019 (GBD 2019) Data Resources. Input Sources Tool: Institute for Health Metrics and Evaluation, DOI [DOI 10.6069/D8QB-JK35, 10.6069/1W19-VX76, DOI 10.6069/1W19-VX76]
  • [8] [Anonymous], 2021, CanMED: Cancer Medications Enquiry Database
  • [9] [Anonymous], 2020, Medicare Part B Drug Spending Dashboard
  • [10] ARROW KJ, 1963, AM ECON REV, V53, P941